170 related articles for article (PubMed ID: 1981623)
1. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
Rao ML; Gross G; Strebel B; Bräunig P; Huber G; Klosterkötter J
Psychiatry Res; 1990 Dec; 34(3):243-57. PubMed ID: 1981623
[TBL] [Abstract][Full Text] [Related]
2. Prolactin shifts after neuroleptic withdrawal.
Green AI; Faraone SV; Brown WA
Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.
Rao ML; Gross G; Strebel B; Halaris A; Huber G; Bräunig P; Marler M
Biol Psychiatry; 1994 Feb; 35(3):151-63. PubMed ID: 7909693
[TBL] [Abstract][Full Text] [Related]
4. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.
Glovinsky D; Kalogeras KT; Kirch DG; Suddath R; Wyatt RJ
Schizophr Res; 1994 Feb; 11(3):273-6. PubMed ID: 7910756
[TBL] [Abstract][Full Text] [Related]
6. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
8. Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: Window to the brain?
Rao ML; Strebel B; Gross G; Huber G
Amino Acids; 1992 Feb; 2(1-2):111-8. PubMed ID: 24194278
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia.
Rao ML; Strebel B; Halaris A; Gross G; Bräunig P; Huber G; Marler M
Psychiatry Res; 1995 Jun; 57(1):21-39. PubMed ID: 7568556
[TBL] [Abstract][Full Text] [Related]
10. Hyperdopaminergia in schizophreniform psychosis: a chronobiological study.
Rao ML; Gross G; Halaris A; Huber G; Marler M; Strebel B; Bräunig P
Psychiatry Res; 1993 May; 47(2):187-203. PubMed ID: 8341771
[TBL] [Abstract][Full Text] [Related]
11. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
[TBL] [Abstract][Full Text] [Related]
12. Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients.
Xiu MH; Chen S; Wang F; Cao LY; Qi LY; Chen DC; Wu GY; Lu L; Kosten TA; Kosten TR; Zhang XY
Schizophr Res; 2008 Dec; 106(2-3):369-70. PubMed ID: 18838250
[No Abstract] [Full Text] [Related]
13. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.
Rapaport MH; Lohr JB
Acta Psychiatr Scand; 1994 Nov; 90(5):311-5. PubMed ID: 7872033
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine.
Tortorella A; Monteleone P; Fabrazzo M; Viggiano A; De Luca L; Maj M
Neuropsychobiology; 2001; 44(4):167-71. PubMed ID: 11702015
[TBL] [Abstract][Full Text] [Related]
15. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
[TBL] [Abstract][Full Text] [Related]
16. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
[TBL] [Abstract][Full Text] [Related]
17. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC
Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780
[TBL] [Abstract][Full Text] [Related]
18. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Mateos JJ; Lomeña F; Parellada E; Mireia F; Fernandez-Egea E; Pavia J; Prats A; Pons F; Bernardo M
Psychopharmacology (Berl); 2007 Apr; 191(3):805-11. PubMed ID: 17019564
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
Wiesel FA
Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
